| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
India’s Lupin Acquires Majority Stake In Japanese Generic Manufacturer Kyowa
Posted on 10/12/2007 14:54 PM | Link | Post Comment
by Jonathan M. Block
PharmAsia News
Demonstrating the growing power of Indian pharmaceutical companies, Mumbai-based Lupin Limited has acquired a majority stake in Japanese generic manufacturer Kyowa Pharmaceutical Industry Co.
Financial details of the deal, which was announced Oct. 10, were not disclosed, though Osaka-based Kyowa had sales of ¥7.4 billion ($63.95 billion) for the year ended March 2007.
Lupin, like other Indian pharmas including Dr. Reddy's and Ranbaxy, is increasingly looking to develop new chemical entities, with a focus on anti-tuberculosis, anti-infectives (cephalosporins) and cardiovascular therapies. It also has a presence in diabetes, NSAIDs and asthma.
In India, Lupin filed an IND in September 2002 for a migraine medication given intra-nasally. Other compounds in TB, psoriasis and anti-inflammatories are in pre-clinical stages.
Lupin also is conducting research on novel drug delivery systems, including oral controlled-release systems and advance drug delivery systems. The company launched the world's first once-a-day cefadroxil tablet (Odoxil OD) in November 2003.
The firm operates a generics business, as well.
Kyowa’s product portfolio includes therapies in the psychiatric and neurological, CV, respiratory and allergy, and digestive system categories. The company markets its generics under the registered brand AMEL.
Kyowa and Lupin have worked together since August 2005, when the firms signed a Japanese marketing deal focused on finished formulations.
Commenting on this latest deal, Lupin Chairman Desh Bandhu Gupta said, "This is a very significant part of our strategy to tap leading global markets and establishes a beachhead in the second largest pharmaceutical market in the world."
Kyowa Chairman Y. Sugiura added, "I am delighted that Lupin Limited is acquiring a majority stake in Kyowa and I am sure that with its global vision, Lupin will be able to propel Kyowa to the top league in Japan."
PharmAsia News is a regular contributor to BioHealth Investor
_______________
PharmAsia News
Demonstrating the growing power of Indian pharmaceutical companies, Mumbai-based Lupin Limited has acquired a majority stake in Japanese generic manufacturer Kyowa Pharmaceutical Industry Co.
Financial details of the deal, which was announced Oct. 10, were not disclosed, though Osaka-based Kyowa had sales of ¥7.4 billion ($63.95 billion) for the year ended March 2007.
Lupin, like other Indian pharmas including Dr. Reddy's and Ranbaxy, is increasingly looking to develop new chemical entities, with a focus on anti-tuberculosis, anti-infectives (cephalosporins) and cardiovascular therapies. It also has a presence in diabetes, NSAIDs and asthma.
In India, Lupin filed an IND in September 2002 for a migraine medication given intra-nasally. Other compounds in TB, psoriasis and anti-inflammatories are in pre-clinical stages.
Lupin also is conducting research on novel drug delivery systems, including oral controlled-release systems and advance drug delivery systems. The company launched the world's first once-a-day cefadroxil tablet (Odoxil OD) in November 2003.
The firm operates a generics business, as well.
Kyowa’s product portfolio includes therapies in the psychiatric and neurological, CV, respiratory and allergy, and digestive system categories. The company markets its generics under the registered brand AMEL.
Kyowa and Lupin have worked together since August 2005, when the firms signed a Japanese marketing deal focused on finished formulations.
Commenting on this latest deal, Lupin Chairman Desh Bandhu Gupta said, "This is a very significant part of our strategy to tap leading global markets and establishes a beachhead in the second largest pharmaceutical market in the world."
Kyowa Chairman Y. Sugiura added, "I am delighted that Lupin Limited is acquiring a majority stake in Kyowa and I am sure that with its global vision, Lupin will be able to propel Kyowa to the top league in Japan."
PharmAsia News is a regular contributor to BioHealth Investor
_______________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- e-techblog
- Wishing Wealth
- Financial Skeptic
- Don't Mess With Taxes
- Millionaire Now! by Larry Nusbaum
- 360 Digest
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
The Swing of Things - Thu Jul 17, 2008 09:36AM
I used to make a pretty good living sharing hard won [read more]
I used to make a pretty good living sharing hard won [read more]
<< My Home | TheMoneyBlogs Home